FibroBiologics, Inc. Common Stock (FBLG) Stock Forecast & Price Target
FibroBiologics, Inc. Common Stock · NASDAQ
$1.41+0.01 (+0.36%)
15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering FibroBiologics, Inc. Common Stock, 1 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $6.00 to $7.00, so the covering firms are broadly aligned. The average target of $6.50 sits 363% above the current $1.41. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.63 next quarter toward $-3.25 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy133%
Hold267%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to FibroBiologics, Inc. Common Stock.
As of Aug, 1 of 3 firms rate FBLG a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
FBLG EPS & revenue forecast
EPS · NEXT QUARTER
$-0.63
Range $-0.63 – $-0.63 · 1 analysts · +5% YoY
Next period, 1 analysts expect FibroBiologics, Inc. Common Stock to earn $-0.63 a share (range $-0.63 – $-0.63), versus $-0.60 a year earlier. Full-year consensus is $-3.00, growing to $-3.25 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering FibroBiologics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FBLG.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #87
Buy
$6.00+327.0% to target
Overall win rate
54%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #407
Hold
No targeton FBLG
Overall win rate
22%
+ Follow
#3
Michael Okunewitch
Maxim Group
Hold
No targeton FBLG
Coverage
—
+ Follow
#4
EP
Elemer Piros
Rodman & Renshaw
Buy
$12.00+754.1% to target
Coverage
—
+ Follow
FBLG stock forecast FAQ
What is FBLG's average 12-month price target?+
The 1 analysts with a live target average $6.50 for FibroBiologics, Inc. Common Stock over the next 12 months, ranging from a $7.00 high to a $6.00 low.
Is FBLG stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 1 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for FBLG?+
The Street-high target is $7.00, and the Street-low is $6.00 (HC Wainwright & Co.). The average of all 1 active targets is $6.50.
How many Wall Street analysts cover FBLG?+
3 analysts have an active rating on FibroBiologics, Inc. Common Stock, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering FBLG?+
Among analysts who currently cover FBLG, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #87). Their current call is Buy with a $6.00 target.
What is FibroBiologics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.63 per share (range $-0.63 – $-0.63) across 1 analysts. Full-year EPS is projected at $-3.00, rising to $-3.25 the following year.
How much revenue is FibroBiologics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading FBLG lately?+
As of Aug, 1 of 3 firms rate FBLG a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FBLG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
